Cytochrome P450 (CYP) 2E1 was the most efficient CYP enzyme that oxidized benzene to soluble and covalently bound metabolites in rat and human liver microsomes. The covalent binding was due mostly to the formation of benzoquinone (BQ), the oxidation product of hydroquinone (HQ), and was inversely related to the formation of soluble metabolites. In rats, inhalation of benzene (4 mg/liter of air) caused a rapid destruction of CYP2B1 previously induced by phenobarbital. The ability of benzene metabolites to destroy liver microsomal CYP in vitro decreased in the order BQ > HQ > catechol > phenol. The destruction was reversed by ascorbate and diminished by alpha-tocopherol, suggesting that HQ was not toxic, whereas BQ and semiquinone radical (SQ) caused the effect. In the presence of nicotinamide adenine dinucleotide phosphate, reduced (NADPH) the microsomes did not oxidize HQ to BQ, while the formation of superoxide anion radical from both HQ and BQ was markedly quenched. Destruction of CYP in vitro caused by HQ or BQ was not mediated by hydroxyl radical formation or by lipid peroxidation. On the contrary, HQ and BQ inhibited NADPH-mediated lipid peroxidation. Ascorbate induced high levels of hydroxyl radical formation and lipid peroxidation, which were differentially affected by quinones, indicating different mechanisms. Despite reducing the toxicity of HQ and BQ, ascorbate appeared to induce its own toxicity, reflected in high levels of lipid peroxidation. Iron redox cycling played a significant role in the NADPH-induced hydroxyl radical formation but not in that caused by ascorbate; however, lipid peroxidation induced by NADPH or ascorbate was suppressed by ethylenediaminetraacetate, indicating a crucial role of iron. Thus, the data indicate that the quinones destroyed CYP directly and not via oxygen activation or lipid peroxidation.

National Institute of Public Health Praha Czech Republic

Zobrazit více v PubMed

J Biol Chem. 1964 Jul;239:2370-8 PubMed

Biochemistry. 1988 Mar 22;27(6):1925-34 PubMed

J Biol Chem. 1974 Oct 10;249(19):6302-10 PubMed

Mol Pharmacol. 1977 Nov;13(6):993-1004 PubMed

Methods Enzymol. 1978;52:302-10 PubMed

Biochem Biophys Res Commun. 1988 Nov 30;157(1):55-60 PubMed

Carcinogenesis. 1989 Mar;10(3):441-5 PubMed

Biochemistry. 1989 May 16;28(10):4499-504 PubMed

Carcinogenesis. 1989 Sep;10(9):1713-7 PubMed

Biochem Pharmacol. 1990 Apr 15;39(8):1393-5 PubMed

Chem Biol Interact. 1990;75(1):71-81 PubMed

Drug Metab Dispos. 1992 Mar-Apr;20(2):137-41 PubMed

Arch Toxicol. 1993;67(4):237-43 PubMed

Environ Health Perspect. 1993 Apr;100:293-306 PubMed

Carcinogenesis. 1993 Dec;14(12):2477-86 PubMed

Toxicology. 1994 Mar 25;89(1):25-33 PubMed

Biochem Pharmacol. 1994 Jun 15;47(12):2233-42 PubMed

Carcinogenesis. 1994 Sep;15(9):1799-806 PubMed

J Biol Chem. 1951 Nov;193(1):265-75 PubMed

Biochemistry. 1981 Oct 13;20(21):6006-12 PubMed

J Reticuloendothel Soc. 1981 Nov;30(5):359-72 PubMed

Mol Pharmacol. 1984 Jul;26(1):105-11 PubMed

Arch Biochem Biophys. 1985 Apr;238(1):43-8 PubMed

Biochemistry. 1985 Jun 18;24(13):3254-63 PubMed

J Toxicol Environ Health. 1985;16(5):673-8 PubMed

Biochem Int. 1986 Aug;13(2):391-6 PubMed

Chem Biol Interact. 1988;64(3):267-80 PubMed

Arch Biochem Biophys. 1973 Oct;158(2):842-52 PubMed